8-K Announcements
6Material company update
Apr 23, 2026·SEC
Material company update
Jan 29, 2026·SEC
Material company update
Nov 4, 2025·SEC
Utah Medical Products, Inc.(UTMD)Earnings, Financials & Key Ratios
UTMD•NASDAQ
19.3× P/E·Price updated Jun 19, 2026
AboutUtah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN tool to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices through direct customer service and sales force, independent consultants, and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah.Show more
- Revenue$39M-5.8%
- EBITDA$14M-12.3%
- Net Income$11M-18.7%
- EPS (Diluted)3.48-12.1%
- Gross Margin51.6%-12.6%
- EBITDA Margin37.26%-6.9%
- Operating Margin29.6%-10.9%
- Net Margin29.3%-13.6%
- ROE9.54%-15.5%
UTMD Key Insights
Utah Medical Products, Inc. (UTMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓FCF machine: 37.2% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Share count reduced 7.5% through buybacks
- ✓Healthy 5Y average net margin of 31.6%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when UTMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
UTMD Price & Volume
Utah Medical Products, Inc. (UTMD) stock price & volume — 10-year historical chart
Loading chart...
UTMD Growth Metrics
Utah Medical Products, Inc. (UTMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-0.42%
5 Years-1.8%
3 Years-9.68%
TTM-5.83%
Profit CAGR
10 Years-0.48%
5 Years0.89%
3 Years-11.84%
TTM-18.66%
EPS CAGR
10 Years1.03%
5 Years3.43%
3 Years-8.35%
TTM-11.9%
Return on Capital
10 Years16.46%
5 Years13.67%
3 Years11.31%
Last Year9.55%
UTMD Recent Earnings
Utah Medical Products, Inc. (UTMD) EPS & revenue vs analyst estimates — last 4 quarters
Q2 2026Latest
Apr 23, 2026Metric
Actual
Est
EPS
$0.82
—
Rev
$9M
—
Q1 2026
Jan 29, 2026Metric
Actual
Est
EPS
$0.80
—
Rev
$9M
—
Q4 2025
Oct 23, 2025Metric
Actual
Est
EPS
$0.82
—
Rev
$10M
—
Q3 2025
Jul 24, 2025Metric
Actual
Est
EPS
$0.94
—
Rev
$10M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 23, 2026 | $0.82 | $9M |
| Q1 2026 | Jan 29, 2026 | $0.80 | $9M |
| Q4 2025 | Oct 23, 2025 | $0.82 | $10M |
| Q3 2025 | Jul 24, 2025 | $0.94 | $10M |
Based on last 12 quarters of dataView full earnings history →
UTMD Peer Comparison
Utah Medical Products, Inc. (UTMD) competitors in Patient monitoring and respiratory care — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 MMSI | 4.01B | 67.22 | 31.56 | 11.66% | 9.03% | 8.95% | 0.57 | |
 LMAT | 2.14B | 93.95 | 37.28 | 13.53% | 24.35% | 16.19% | 0.47 | |
 ANGO | 505.13M | 12.15 | -14.64 | -3.76% | -9.02% | -15.71% | ||
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 TNDM | 1.05B | 15.30 | -5.03 | 7.93% | -9.2% | -68.29% | 2.86 | |
 NTRA | 33.14B | 231.41 | -152.24 | 35.9% | -9.05% | -15.13% | 0.13 | |
 INMD | 849.01M | 13.40 | 9.37 | -6.16% | 23.27% | 13.28% | 0.02 |
Compare UTMD vs Peers
Utah Medical Products, Inc. (UTMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
UTMD Income Statement
Utah Medical Products, Inc. (UTMD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 41.41M | 42M | 46.9M | 42.18M | 49.05M | 52.28M | 50.22M | 40.9M | 38.52M |
Revenue Growth % | 5.38% | 1.41% | 11.68% | -10.08% | 16.3% | 6.58% | -3.93% | -18.56% | -5.83% |
Cost of Goods Sold | 15.02M | 15.69M | 17.44M | 16.63M | 18.14M | 20.09M | 20.19M | 16.76M | 18.64M |
COGS % of Revenue | 36.27% | 37.36% | 37.18% | 39.43% | 36.97% | 38.42% | 40.19% | 40.98% | 48.4% |
Gross Profit | 26.39M▲ 0% | 26.31M▼ 0.3% | 29.47M▲ 12.0% | 25.55M▼ 13.3% | 30.92M▲ 21.0% | 32.2M▲ 4.1% | 30.04M▼ 6.7% | 24.14M▼ 19.6% | 19.88M▼ 17.7% |
Gross Margin % | 63.73% | 62.64% | 62.82% | 60.57% | 63.03% | 61.58% | 59.81% | 59.03% | 51.6% |
Gross Profit Growth % | 11.42% | -0.34% | 12.01% | -13.3% | 21.02% | 4.14% | -6.7% | -19.63% | -17.68% |
Operating Expenses | 7.38M | 7.61M | 11.83M | 11.84M | 12.04M | 12.41M | 13.26M | 10.55M | 8.47M |
OpEx % of Revenue | 17.83% | 18.12% | 25.23% | 28.07% | 24.54% | 23.73% | 26.4% | 25.79% | 22% |
Selling, General & Admin | 6.94M | 7.16M | 11.35M | 11.35M | 11.51M | 11.91M | 12.7M | 5.57M | 7.8M |
SG&A % of Revenue | 16.75% | 17.04% | 24.2% | 26.92% | 23.47% | 22.79% | 25.29% | 13.61% | 20.26% |
Research & Development | 447K | 454K | 483K | 486K | 526K | 493K | 560K | 813K | 668K |
R&D % of Revenue | 1.08% | 1.08% | 1.03% | 1.15% | 1.07% | 0.94% | 1.11% | 1.99% | 1.73% |
Other Operating Expenses | 54K | 0 | 0 | 0 | 0 | 0 | 0 | 4.17M | 0 |
Operating Income | 19.01M▲ 0% | 18.7M▼ 1.7% | 17.63M▼ 5.7% | 13.71M▼ 22.3% | 18.88M▲ 37.7% | 19.79M▲ 4.8% | 16.78M▼ 15.2% | 13.59M▼ 19.0% | 11.4M▼ 16.1% |
Operating Margin % | 45.9% | 44.52% | 37.59% | 32.5% | 38.49% | 37.85% | 33.4% | 33.23% | 29.6% |
Operating Income Growth % | 17.45% | -1.65% | -5.7% | -22.25% | 37.73% | 4.82% | -15.22% | -18.97% | -16.12% |
EBITDA | 21.78M | 21.65M | 24.51M | 20.92M | 26.16M | 26.87M | 23.14M | 16.36M | 14.35M |
EBITDA Margin % | 52.6% | 51.56% | 52.26% | 49.59% | 53.34% | 51.4% | 46.08% | 40.01% | 37.26% |
EBITDA Growth % | 14.53% | -0.6% | 13.21% | -14.67% | 25.08% | 2.71% | -13.87% | -29.29% | -12.29% |
D&A (Non-Cash Add-back) | 2.77M | 2.96M | 6.88M | 7.21M | 7.28M | 7.08M | 6.37M | 2.77M | 2.95M |
EBIT | 19.01M | 18.7M | 17.63M | 13.71M | 18.88M | 19.79M | 18.44M | 13.59M | 14.11M |
Net Interest Income | 0 | 0 | 254K | 112K | 166K | 661K | 0 | 3.37M | 0 |
Interest Income | 0 | 0 | 254K | 112K | 166K | 661K | 0 | 3.37M | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 71K | 762K | 252K | 132K | 181K | 869K | 3.31M | 3.21M | 2.71M |
Pretax Income | 19.08M▲ 0% | 19.46M▲ 2.0% | 17.88M▼ 8.1% | 13.84M▼ 22.6% | 19.06M▲ 37.7% | 20.66M▲ 8.4% | 20.09M▼ 2.8% | 16.8M▼ 16.4% | 14.11M▼ 16.0% |
Pretax Margin % | 46.08% | 46.33% | 38.13% | 32.81% | 38.86% | 39.52% | 40% | 41.08% | 36.63% |
Income Tax | 10.58M | 904K | 3.16M | 3.04M | 4.27M | 4.19M | 3.45M | 2.93M | 2.82M |
Effective Tax Rate % | 55.43% | 4.65% | 17.65% | 21.98% | 22.42% | 20.26% | 17.19% | 17.43% | 20.01% |
Net Income | 8.51M▲ 0% | 18.55M▲ 118.2% | 14.73M▼ 20.6% | 10.8M▼ 26.7% | 14.79M▲ 37.0% | 16.47M▲ 11.4% | 16.64M▲ 1.0% | 13.87M▼ 16.6% | 11.29M▼ 18.7% |
Net Margin % | 20.54% | 44.18% | 31.4% | 25.6% | 30.15% | 31.51% | 33.12% | 33.92% | 29.3% |
Net Income Growth % | -29.87% | 118.15% | -20.63% | -26.68% | 36.95% | 11.39% | 0.98% | -16.6% | -18.65% |
Net Income (Continuing) | 8.51M | 18.55M | 14.73M | 10.8M | 14.79M | 16.47M | 16.64M | 13.87M | 11.29M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 2.28▲ 0% | 4.95▲ 117.1% | 3.94▼ 20.4% | 2.94▼ 25.4% | 4.04▲ 37.4% | 4.52▲ 11.9% | 4.57▲ 1.1% | 3.96▼ 13.3% | 3.48▼ 12.1% |
EPS Growth % | -29.19% | 117.11% | -20.4% | -25.38% | 37.41% | 11.88% | 1.11% | -13.35% | -12.12% |
EPS (Basic) | 2.29 | 4.97 | 3.96 | 2.95 | 4.05 | 4.53 | 4.57 | 3.96 | 3.41 |
Diluted Shares Outstanding | 3.74M | 3.75M | 3.74M | 3.67M | 3.66M | 3.64M | 3.64M | 3.5M | 3.24M |
Basic Shares Outstanding | 3.72M | 3.73M | 3.72M | 3.66M | 3.65M | 3.64M | 3.64M | 3.5M | 3.31M |
Dividend Payout Ratio | 34.74% | 21.7% | 27.92% | 38.12% | 77.53% | 19.2% | 25.74% | 30.7% | 35.29% |
UTMD Balance Sheet
Utah Medical Products, Inc. (UTMD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 49.19M | 60.9M | 54.88M | 62.26M | 73.16M | 89.92M | 106.27M | 96.33M | 97.74M |
Cash & Short-Term Investments | 39.95M | 51.11M | 42.79M | 51.59M | 60.97M | 75.05M | 92.87M | 82.98M | 85.76M |
Cash Only | 39.88M | 51.11M | 42.79M | 51.59M | 60.97M | 75.05M | 92.87M | 82.98M | 85.76M |
Short-Term Investments | 80K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 3.62M | 3.96M | 4.74M | 4.1M | 5.13M | 5.54M | 3.39M | 4.09M | 3.52M |
Days Sales Outstanding | 31.93 | 34.38 | 36.9 | 35.52 | 38.18 | 38.66 | 24.64 | 36.53 | 33.37 |
Inventory | 5.24M | 5.41M | 6.91M | 6.22M | 6.6M | 8.81M | 9.58M | 8.81M | 7.93M |
Days Inventory Outstanding | 127.44 | 125.91 | 144.7 | 136.56 | 132.74 | 160.17 | 173.26 | 191.91 | 155.34 |
Other Current Assets | 0 | 13K | 0 | 0 | 1K | 0 | 429K | 448K | 529K |
Total Non-Current Assets | 43.56M | 38.87M | 54.9M | 49.48M | 42.48M | 33.95M | 29.19M | 26.21M | 24.8M |
Property, Plant & Equipment | 11.62M | 10.36M | 10.73M | 11.33M | 10.62M | 10.22M | 10.55M | 9.76M | 9.91M |
Fixed Asset Turnover | 3.56x | 4.05x | 4.37x | 3.72x | 4.62x | 5.11x | 4.76x | 4.19x | 3.89x |
Goodwill | 14.09M | 13.7M | 13.96M | 14.16M | 14.1M | 13.35M | 13.69M | 13.58M | 14.05M |
Intangible Assets | 17.84M | 14.8M | 30.21M | 23.99M | 17.76M | 10.38M | 4.95M | 2.87M | 840K |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | -3.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 92.75M▲ 0% | 99.77M▲ 7.6% | 109.79M▲ 10.0% | 111.75M▲ 1.8% | 115.64M▲ 3.5% | 123.87M▲ 7.1% | 135.46M▲ 9.4% | 122.54M▼ 9.5% | 122.54M▲ 0.0% |
Asset Turnover | 0.45x | 0.42x | 0.43x | 0.38x | 0.42x | 0.42x | 0.37x | 0.33x | 0.31x |
Asset Growth % | 21.1% | 7.57% | 10.04% | 1.78% | 3.48% | 7.12% | 9.35% | -9.54% | 0% |
Total Current Liabilities | 5.28M | 5.26M | 3.45M | 3.79M | 3.75M | 5.96M | 4.71M | 3.76M | 2.6M |
Accounts Payable | 934K | 975K | 1.1M | 788K | 761K | 1.22M | 769K | 543K | 911K |
Days Payables Outstanding | 22.7 | 22.68 | 22.98 | 17.3 | 15.31 | 22.13 | 13.9 | 11.83 | 17.83 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 56K | 0 |
Deferred Revenue (Current) | 0 | 0 | -38K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3.15M | 3.19M | 604K | 116K | 96K | 204K | 257K | 55K | 1.69M |
Current Ratio | 9.32x | 11.58x | 15.92x | 16.42x | 19.53x | 15.09x | 22.56x | 25.64x | 37.62x |
Quick Ratio | 8.32x | 10.55x | 13.91x | 14.78x | 17.77x | 13.61x | 20.53x | 23.29x | 34.57x |
Cash Conversion Cycle | 136.68 | 137.61 | 158.62 | 154.78 | 155.61 | 176.7 | 183.99 | 216.62 | 170.88 |
Total Non-Current Liabilities | 9.34M | 5.52M | 5.25M | 5.13M | 4.75M | 3.66M | 2.44M | 1.35M | 676K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 376K | 335K | 396K | 341K | 295K | 282K | 225K |
Deferred Tax Liabilities | 3.56M | 3.08M | 2.76M | 2.8M | 2.68M | 2.06M | 1.44M | 1.07M | 451K |
Other Non-Current Liabilities | 5.79M | 2.44M | 2.11M | 2M | 1.68M | 1.26M | 698K | 0 | 0 |
Total Liabilities | 14.62M | 10.78M | 8.7M | 8.92M | 8.5M | 9.62M | 7.14M | 5.11M | 3.27M |
Total Debt | 0 | 0 | 376K | 335K | 396K | 341K | 295K | 338K | 225K |
Net Debt | -39.88M | -51.11M | -42.41M | -51.26M | -60.58M | -74.71M | -92.57M | -82.69M | -85.53M |
Debt / Equity | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
Debt / EBITDA | - | - | 0.02x | 0.02x | 0.02x | 0.01x | 0.01x | 0.02x | 0.02x |
Net Debt / EBITDA | -1.83x | -2.36x | -1.73x | -2.45x | -2.32x | -2.78x | -4.00x | -5.05x | -5.96x |
Interest Coverage | - | - | - | - | - | - | - | - | - |
Total Equity | 78.12M▲ 0% | 88.99M▲ 13.9% | 101.09M▲ 13.6% | 102.82M▲ 1.7% | 107.14M▲ 4.2% | 114.25M▲ 6.6% | 128.31M▲ 12.3% | 117.43M▼ 8.5% | 119.27M▲ 1.6% |
Equity Growth % | 12.82% | 13.91% | 13.6% | 1.71% | 4.2% | 6.64% | 12.31% | -8.48% | 1.57% |
Book Value per Share | 20.91 | 23.74 | 27.04 | 28.00 | 29.27 | 31.36 | 35.28 | 33.52 | 36.81 |
Total Shareholders' Equity | 78.12M | 88.99M | 101.09M | 102.82M | 107.14M | 114.25M | 128.31M | 117.43M | 119.27M |
Common Stock | 37K | 37K | 37K | 36K | 37K | 36K | 36K | 33K | 32K |
Retained Earnings | 85.62M | 100.12M | 110.82M | 110.95M | 115.31M | 126.01M | 138.34M | 129.3M | 128.65M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -8.34M | -11.29M | -9.78M | -8.28M | -9.05M | -12.04M | -10.66M | -11.91M | -9.42M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
UTMD Cash Flow Statement
Utah Medical Products, Inc. (UTMD) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 16.91M | 16.83M | 17.06M | 20.14M | 21.2M | 21.15M | 22.28M | 14.83M | 14.69M |
Operating CF Margin % | 40.83% | 40.08% | 36.36% | 47.74% | 43.22% | 40.45% | 44.36% | 36.26% | 38.14% |
Operating CF Growth % | 16.38% | -0.44% | 1.32% | 18.06% | 5.29% | -0.26% | 5.36% | -33.44% | -0.94% |
Net Income | 8.51M | 18.55M | 14.73M | 10.8M | 14.79M | 16.47M | 16.64M | 13.87M | 11.29M |
Depreciation & Amortization | 2.77M | 2.96M | 6.88M | 7.21M | 7.28M | 7.08M | 6.37M | 2.85M | 0 |
Stock-Based Compensation | 129K | 64K | 113K | 160K | 166K | 183K | 225K | 256K | 373K |
Deferred Taxes | -658K | -326K | -396K | -26K | -92K | -401K | -681K | -338K | 0 |
Other Non-Cash Items | 21K | -373K | 53K | 3K | 63K | 36K | -33K | -4K | 2.72M |
Working Capital Changes | 6.14M | -4.04M | -4.32M | 1.99M | -1.01M | -2.23M | -233K | -1.8M | 317K |
Change in Receivables | -242K | -496K | -738K | 662K | -1.13M | -525K | 2.27M | -781K | 333K |
Change in Inventory | -467K | -244K | -1.69M | 924K | -485K | -2.35M | -670K | 587K | 1.2M |
Change in Payables | 9K | 52K | 114K | -308K | -23K | 464K | -456K | -73K | 211K |
Cash from Investing | -1.6M | 534K | -21.54M | -860K | -552K | -818K | -639K | -208K | -371K |
Capital Expenditures | -1.6M | -402K | -540K | -860K | -552K | -809K | -639K | -235K | -371K |
CapEx % of Revenue | 3.86% | 0.96% | 1.15% | 2.04% | 1.13% | 1.55% | 1.27% | 0.57% | 0.96% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 862K | -21M | 0 | 0 | -9K | 0 | 27K | 0 |
Cash from Financing | -2.65M | -4.78M | -4.23M | -10.73M | -10.9M | -5.48M | -4.17M | -23.84M | -12.34M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | -1.21M | -398K | -6.98M | 0 | -2.5M | 0 | -19.97M | -8.36M |
Dividends Paid | -2.96M | -4.03M | -4.11M | -4.12M | -11.46M | -3.16M | -4.28M | -4.26M | -3.98M |
Share Repurchases | -2.85M | -1.21M | -398K | -6.98M | 0 | -2.5M | 0 | -19.97M | -8.36M |
Other Financing | 302K | 454K | 283K | 358K | 560K | 174K | 117K | 390K | 0 |
Net Change in Cash | 13.58M▲ 0% | 11.24M▼ 17.2% | -8.32M▼ 174.1% | 8.8M▲ 205.7% | 9.38M▲ 6.6% | 14.08M▲ 50.0% | 17.82M▲ 26.6% | -9.89M▼ 155.5% | 2.78M▲ 128.1% |
Free Cash Flow | 15.31M▲ 0% | 16.43M▲ 7.3% | -4.48M▼ 127.3% | 19.28M▲ 529.9% | 20.65M▲ 7.1% | 20.33M▼ 1.6% | 21.64M▲ 6.5% | 14.6M▼ 32.6% | 14.32M▼ 1.9% |
FCF Margin % | 36.97% | 39.13% | -9.56% | 45.7% | 42.1% | 38.88% | 43.09% | 35.68% | 37.18% |
FCF Growth % | 36.39% | 7.32% | -127.29% | 529.91% | 7.13% | -1.56% | 6.46% | -32.56% | -1.88% |
FCF per Share | 4.10 | 4.38 | -1.20 | 5.25 | 5.64 | 5.58 | 5.95 | 4.17 | 4.42 |
FCF Conversion (FCF/Net Income) | 1.99x | 0.91x | 1.16x | 1.86x | 1.43x | 1.28x | 1.34x | 1.07x | 1.30x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 5.15M | 4.85M | 5.3M | 3.19M | 4.62M | 4.97M | 4.83M | 4.64M | 4M |
UTMD Key Ratios
Utah Medical Products, Inc. (UTMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 17.46% | 11.54% | 22.21% | 15.5% | 10.59% | 14.09% | 14.88% | 13.72% | 11.29% | 9.54% |
Return on Invested Capital (ROIC) | 27.22% | 35.15% | 36.84% | 27.39% | 18.65% | 28.86% | 34.48% | 33.43% | 28.91% | 24.96% |
Gross Margin | 60.28% | 63.73% | 62.64% | 62.82% | 60.57% | 63.03% | 61.58% | 59.81% | 59.03% | 51.6% |
Net Margin | 30.86% | 20.54% | 44.18% | 31.4% | 25.6% | 30.15% | 31.51% | 33.12% | 33.92% | 29.3% |
Debt / Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
FCF Conversion | 1.20x | 1.99x | 0.91x | 1.16x | 1.86x | 1.43x | 1.28x | 1.34x | 1.07x | 1.30x |
Revenue Growth | -2.14% | 5.38% | 1.41% | 11.68% | -10.08% | 16.3% | 6.58% | -3.93% | -18.56% | -5.83% |
Related:UTMD Dividend History·UTMD Revenue History·UTMD Price History·UTMD P/E History·UTMD Financial Ratios·UTMD Institutional Holders
UTMD SEC Filings & Documents
Utah Medical Products, Inc. (UTMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
UTMD Frequently Asked Questions
Utah Medical Products, Inc. (UTMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Utah Medical Products, Inc. (UTMD) reported $38.5M in revenue for fiscal year 2025. This represents a 0% decrease from $38.7M in 1996.
Utah Medical Products, Inc. (UTMD) saw revenue decline by 5.8% over the past year.
Yes, Utah Medical Products, Inc. (UTMD) is profitable, generating $11.3M in net income for fiscal year 2025 (29.3% net margin).
Dividend & Returns
Yes, Utah Medical Products, Inc. (UTMD) pays a dividend with a yield of 1.83%. This makes it attractive for income-focused investors.
Utah Medical Products, Inc. (UTMD) has a return on equity (ROE) of 9.5%. This is below average, suggesting room for improvement.
Utah Medical Products, Inc. (UTMD) generated $14.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.